Acasti Pharma Inc. (ACST)

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the FDA

Expects lead asset to complete PK Bridging Study in early 2022, with potential to advance directly into a Phase 3 clinical safety trial for Subarachnoid Hemorrhage

Combination creates a unique rare disease company with innovative drug delivery technologies, and is expected to have ~$64M in cash at closing to advance lead clinical assets

CaPreMD

Acasti Pharma propose un médicament à visée cardiovasculaire qui est potentiellement le meilleur de sa catégorie destiné au traitement de l’hypertriglycéridémie.

Notre Science

Extrait de l’huile de krill, CaPre est conçu pour offrir un tiercé gagnant de bienfaits sur la santé cardiométabolique aux patients dans le besoin.

L’équipe

Nos dirigeants et scientifiques passionnés apportent des décennies d’expérience en développement et en commercialisation de nouvelles thérapies.

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the FDA

Expects lead asset to complete PK Bridging Study in early 2022, with potential to advance directly into a Phase 3 clinical safety trial for Subarachnoid Hemorrhage

Combination creates a unique rare disease company with innovative drug delivery technologies, and is expected to have ~$64M in cash at closing to advance lead clinical assets

Excellence dans la Recherche

CaPreMD

Notre Science

L’équipe